Monitor stockholder vote given the required majority of combined voting power; no competing bid emerged during go-shop; deal expected to close by end of Q4 2026 subject to conditions including stockholder approval and Alcon agreements remaining in effect
Price Chart
Executive Summary
Lifecore Biomedical filed a preliminary proxy statement (PREM14A) for a special meeting to approve its acquisition by an affiliate of Webster Equity Partners for $6.28 per share in cash plus one contingent value right (CVR) per share, with up to $160 million in aggregate milestone payments tied to 2028-2030 revenue and EBITDA targets. The board unanimously recommends the deal, supported by a fairness opinion from Craig-Hallum, and voting agreements covering ~27.34% of the combined voting power are in place. The go-shop period ended with no competing proposal received.
Key Financial Metrics
Key Facts
- Merger consideration of $6.28 per share in cash plus one CVR per share for common stock; Series A Preferred stock receives Conversion Amount plus CVRs per convertible share
- CVRs provide up to $160 million in aggregate milestone payments based on 2028 revenue, 2029 revenue and 2030 EBITDA milestones
- Board unanimously recommends FOR the merger agreement, advisory compensation and adjournment proposals
- Craig-Hallum delivered fairness opinion that common stock merger consideration is fair to common stockholders
- Voting agreements with Wynnefield and Legion stockholders cover ~27.34% of combined voting power
- Go-shop period ended October 28, 2026 with no acquisition proposal received
- Total funds needed at closing approximately $550 million, funded by $400 million equity commitment and $150 million debt commitment including $35 million from Alcon
- HSR waiting period received early termination; expected close by end of Q4 2026
- Company termination fee of $9,957,716 (or $7,468,287 during go-shop); reverse termination fee of $9,957,716
- Reverse termination fee of $16,181,288 payable by Parent if merger agreement terminated in certain circumstances
Financial Impact
Cash consideration of $6.28 per share for common stock; maximum aggregate CVR payments of $160 million; total funds needed at closing approximately $550 million
Risk Factors
- Stockholder approval required; failure to vote or abstention counts as vote against
- CVR milestone payments are contingent and may not be achieved
- Company restricted from capital raising or redeeming Series A Preferred Stock pending closing
- Parent and Merger Sub are newly formed entities with no assets; limited guarantee covers only reverse termination fee and certain damages
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (Primary) | 0001140361-26-041332 |
| Document: ny20082863x1_ex107.htm | 0001140361-26-041332 |
| Document: 0001140361-26-041332-index-headers.html | 0001140361-26-041332 |
| Document: 0001140361-26-041332-index.html | 0001140361-26-041332 |
| Document: 0001140361-26-041332.txt | 0001140361-26-041332 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 1d ago | PREM14A | $6.48 | awaiting T+1 | awaiting T+1 | $6.40 (−1.23%) |
Oct 20, 2026 11d ago | 8-K | $6.37 $6.37 | · 0.00% | ▲ +1.18% | $6.40 (+0.47%) |
Sep 28, 2026 4w ago | SC 13D/A | $6.59 $6.58 | ▼ −0.15% | ▲ +0.05% | $6.40 (−2.88%) |
Sep 28, 2026 4w ago | DEFA14A | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.40 (−1.84%) |
Sep 28, 2026 4w ago | 8-K | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.40 (−1.84%) |
Sep 28, 2026 4w ago | Press Release | $6.52 $6.59 | ▲ +1.07% | ▲ +1.26% | $6.40 (−1.84%) |
Aug 5, 2026 12w ago | 8-K | $4.44 $4.84 | ▲ +9.01% | ▲ +9.17% | $6.40 (+44.14%) |
Jul 2, 2026 17w ago | 8-K | $5.09 $5.05 | ▲ +0.79% | ▲ +1.66% | $6.40 (−25.74%) |
Jun 15, 2026 19w ago | Press Release | $5.49 $5.35 | ▼ −2.55% | ▼ −1.95% | $6.40 (+16.58%) |
Jun 5, 2026 21w ago | 8-K | $5.57 $5.66 | ▲ +1.62% | ▲ +1.91% | $6.40 (+14.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers